Antagonists: Neostigmine, Sugammadex

Antagonists of neuromuscular blockade: neostigmine and sugammadex

Reversal of neuromuscular blockade is a core Primary FRCA pharmacology topic because it integrates receptor pharmacology, pharmacokinetics, monitoring, perioperative respiratory physiology and patient safety. The two clinically important reversal strategies are fundamentally different: neostigmine increases acetylcholine concentration at the neuromuscular junction and competes indirectly with non-depolarising relaxants, whereas sugammadex physically encapsulates aminosteroid neuromuscular blocking drugs, especially rocuronium, reducing free plasma concentration and creating a concentration gradient away from the effect site.

The exam emphasis is not merely memorising doses. Candidates must understand why neostigmine has a ceiling effect, why it can paradoxically worsen neuromuscular function if given after full recovery, why sugammadex can reverse deep rocuronium block but not benzylisoquinolinium block, and why quantitative monitoring remains essential even when modern reversal agents are used.

Physiology and pharmacological target

The adult neuromuscular junction contains nicotinic acetylcholine receptors of the Nm subtype, classically arranged as pentamers with composition alpha1 beta1 delta epsilon in adults. The fetal or denervated receptor contains gamma rather than epsilon subunit and is distributed extrajunctionally. Each receptor requires binding of two acetylcholine molecules to the alpha subunits to open the ligand-gated cation channel. Sodium influx and potassium efflux produce the end-plate potential; if threshold is reached, voltage-gated sodium channels in the perijunctional membrane generate a propagated muscle action potential.

Non-depolarising neuromuscular blockers are competitive antagonists at Nm receptors. Clinically significant paralysis occurs well before all receptors are occupied because of the large safety margin of neuromuscular transmission. Fade during train-of-four and tetanic stimulation reflects presynaptic nicotinic receptor blockade, reducing mobilisation of acetylcholine during repeated stimulation. Reversal therefore requires restoration of sufficient postsynaptic receptor activation and presynaptic acetylcholine release to abolish fade.

Residual neuromuscular blockade

Residual neuromuscular blockade is usually defined as an adductor pollicis train-of-four ratio less than 0.90 measured with quantitative monitoring. Clinical tests such as head lift, hand grip, tongue protrusion, tidal volume and sustained tetany are insensitive; many patients can lift their head at a TOF ratio of 0.5 to 0.6. The diaphragm often recovers earlier than upper airway dilator muscles, so apparently adequate ventilation may coexist with pharyngeal dysfunction, impaired swallowing and aspiration risk.

Neostigmine

Chemistry and class

Neostigmine is a quaternary ammonium carbamate anticholinesterase. It is permanently charged at physiological pH, poorly lipid soluble and does not cross the blood-brain barrier in clinically relevant amounts. This distinguishes it from physostigmine, a tertiary amine that can enter the CNS. Neostigmine reverses non-depolarising blockade indirectly by inhibiting acetylcholinesterase at the neuromuscular junction, thereby increasing acetylcholine concentration in the synaptic cleft.

Molecular mechanism

Acetylcholinesterase has an anionic site that binds the quaternary ammonium group of acetylcholine and an esteratic site containing catalytic serine. Acetylcholine is hydrolysed extremely rapidly, with turnover approaching 10,000 molecules per second. Neostigmine binds reversibly and carbamylates the esteratic site. The carbamylated enzyme is hydrolysed much more slowly than the acetylated enzyme, producing functional inhibition for approximately 30 to 90 minutes.

The increase in acetylcholine antagonises competitive non-depolarising blockers at postsynaptic Nm receptors and improves presynaptic nicotinic receptor activation. However, this is an indirect competitive strategy. If too many receptors remain occupied by relaxant, acetylcholine cannot restore adequate transmission. Hence neostigmine has a ceiling effect and is unreliable for deep block.

Pharmacodynamics and ceiling effect

Neostigmine is most effective when spontaneous recovery is already established. Giving neostigmine at a post-tetanic count without TOF responses is poor practice. It may take more than 20 to 30 minutes to reach TOF ratio 0.9 after reversal from deeper levels, and some patients will remain inadequately reversed. At higher doses, further acetylcholinesterase inhibition yields little additional benefit because acetylcholinesterase is already substantially inhibited and excess acetylcholine may cause depolarising-type weakness, open-channel block and desensitisation.

A clinically important examination point is that neostigmine given after near-complete recovery can impair neuromuscular transmission, particularly in the presence of volatile anaesthesia, by causing excessive acetylcholine at the endplate and disordered muscle activation. Therefore reversal should be guided by quantitative monitoring, not administered automatically.

Dose and administration

Onset is usually 2 to 5 minutes, peak effect 7 to 11 minutes, and clinically useful duration approximately 45 to 90 minutes. Candidates should avoid claiming that extubation is safe immediately after injection. The time to reliable reversal depends on relaxant, depth of block, volatile anaesthetic concentration, temperature, acid-base status and patient factors.

Pharmacokinetics

In renal impairment, both neostigmine and some neuromuscular blockers may have prolonged elimination. Importantly, the duration of action of neostigmine may be shorter than the residual effect of a long-acting relaxant, allowing recurarisation. Modern anaesthesia should avoid long-acting pancuronium when reliable rapid recovery is required.

Muscarinic effects and antimuscarinic co-administration

Neostigmine is not selective for nicotinic synapses. Increased acetylcholine at muscarinic receptors produces bradycardia, atrioventricular nodal slowing, bronchoconstriction, increased bronchial and salivary secretions, intestinal cramping, nausea, increased peristalsis, miosis and sweating. It is therefore administered with an antimuscarinic, usually glycopyrronium in UK practice.

Neostigmine and glycopyrronium are often supplied as a mixture, for example neostigmine 2.5 mg with glycopyrronium 500 micrograms in 1 ml or 2 ml depending on preparation. Local concentration must be checked: drug errors involving reversal mixtures are common.

Adverse effects and cautions

• Cardiovascular: bradycardia, junctional rhythm, AV block, hypotension or rarely asystole, especially without antimuscarinic or in high vagal tone.
• Respiratory: bronchospasm and increased secretions; relevant in severe asthma or COPD.
• Gastrointestinal: nausea, vomiting, abdominal cramping, increased salivation and peristalsis; theoretical risk with fresh bowel anastomosis is often overstated but ileus and obstruction remain cautions.
• Genitourinary: increased bladder detrusor tone; caution with urinary obstruction.
• Neuromuscular: failure to reverse deep block, recurarisation, and paradoxical weakness after administration when already recovered.

Sugammadex

Chemistry and selectivity

Sugammadex is a modified gamma-cyclodextrin. Cyclodextrins are cyclic oligosaccharides with a hydrophilic exterior and hydrophobic central cavity. Sugammadex has eight negatively charged carboxyl thioether side chains extending from the gamma-cyclodextrin ring. These increase aqueous solubility and provide electrostatic interaction with the positively charged aminosteroid neuromuscular blocker molecule.

It is highly selective for aminosteroid relaxants, especially rocuronium, with lower affinity for vecuronium and much lower affinity for pancuronium. It has no clinically useful effect on benzylisoquinolinium agents such as atracurium, cisatracurium or mivacurium, and it does not reverse suxamethonium.

Mechanism of action

Sugammadex encapsulates free rocuronium in plasma in a 1:1 host-guest complex. The association constant for rocuronium is approximately 10⁷ M^-1, often quoted around 25 million M^-1; affinity for vecuronium is lower, approximately 10⁶ M^-1. Binding rapidly reduces the unbound plasma concentration of rocuronium. Rocuronium then diffuses down its concentration gradient from the neuromuscular junction into plasma, where it is also bound. This reduces receptor occupancy without relying on acetylcholine concentration and explains why sugammadex can reverse deep rocuronium block.

Because the complex is inactive at the nicotinic receptor and is excreted renally, reversal is rapid and usually complete if the dose is adequate for the measured depth of block. Underdosing can produce initial improvement followed by recurrence if redistribution of unbound rocuronium exceeds available sugammadex binding capacity.

Dosing

Doses are licensed on actual body weight. In morbid obesity, this may be costly and produce very large doses. Studies using ideal body weight plus 40 percent or adjusted body weight have shown reasonable recovery in selected moderate block, but underdosing risks recurrence, especially after deep block. For examination and safety, actual body weight remains the conservative licensed answer, particularly for deep block or rescue.

Pharmacokinetics

In severe renal impairment, usually defined as creatinine clearance less than 30 ml/min, elimination is markedly prolonged. The sugammadex-rocuronium complex remains stable, but prolonged exposure raises concerns about recurrence, hypersensitivity, and uncertain long-term safety. Many licences advise avoiding sugammadex in severe renal failure unless benefit outweighs risk. High-flux haemodialysis can remove sugammadex and complex, with substantial reductions over repeated sessions, but this is not an immediate intraoperative reversal strategy.

Adverse effects and interactions

• Hypersensitivity and anaphylaxis: uncommon but well recognised. Reported incidence varies by pharmacovigilance system and dose; estimates range from approximately 1 in several thousand to less than 0.1 percent. It may occur on first exposure.
• Bradycardia: marked bradycardia and rare asystole have been reported, usually within minutes. Treat with anticholinergic or adrenaline according to severity.
• Coagulation tests: transient prolongation of PT and APTT by around 5 to 10 percent has been described, particularly with 16 mg/kg, but clinically important bleeding has not been consistently demonstrated. Caution is reasonable with anticoagulants or major bleeding risk.
• Drug binding interactions: sugammadex can bind steroidal compounds weakly. It may reduce hormonal contraceptive exposure; patients should be advised to use additional non-hormonal contraception for 7 days, equivalent to a missed pill warning.
• Displacement interactions: toremifene and fusidic acid are often cited as theoretical or potential agents that may displace rocuronium from sugammadex or interfere with binding, although major clinical recurrence is rare.
• PONV and pain: nausea, vomiting, cough and dysgeusia have been reported, but many comparisons show fewer muscarinic adverse effects than neostigmine-glycopyrronium.

Comparing neostigmine and sugammadex

Evidence and guidelines

Modern guidance increasingly emphasises quantitative neuromuscular monitoring. The Association of Anaesthetists, ESAIC and ASA practice guidance all support objective monitoring when neuromuscular blockers are used and recommend ensuring TOF ratio at least 0.9 before extubation. The 2023 ASA Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade recommend quantitative rather than qualitative assessment, sugammadex rather than neostigmine for deep, moderate and shallow aminosteroid block in many circumstances, and neostigmine mainly when recovery is minimal or shallow, especially when TOF ratio is 0.4 to 0.9.

Clinical studies consistently show faster recovery with sugammadex than neostigmine. The Cochrane review by Hristovska and colleagues, including over 40 trials and more than 4000 participants, found sugammadex reduced time to TOF ratio 0.9 by about 10 minutes for moderate block and by more than 40 minutes for deep block compared with neostigmine, with fewer composite adverse events including bradycardia, PONV and residual paralysis. Observational data such as the POPULAR study linked neuromuscular blocker exposure and residual block with postoperative pulmonary complications, while large database analyses such as STRONGER reported lower pulmonary complication rates with sugammadex compared with neostigmine, though confounding is inherent in non-randomised designs.

The viva controversy is not whether sugammadex works; it clearly provides faster pharmacological reversal of rocuronium. The issues are cost-effectiveness, availability, anaphylaxis risk, reliance on it instead of airway planning, dosing in obesity, use in severe renal failure, and whether universal sugammadex use improves hard outcomes sufficiently to justify cost in all patients. A balanced FRCA answer states that quantitative monitoring remains mandatory because neither drug guarantees safe recovery if used inappropriately.

Clinical approach to reversal

1. Identify the relaxant: rocuronium and vecuronium can be reversed by sugammadex; atracurium and cisatracurium cannot.
2. Measure depth quantitatively: use acceleromyography, electromyography or kinemyography, ideally at adductor pollicis. Corrugator supercilii better reflects laryngeal muscles for intubation, but adductor pollicis is more conservative for recovery.
3. Optimise physiology: correct hypothermia, respiratory acidosis, severe metabolic alkalosis or acidosis, hypokalaemia, hypermagnesaemia and excessive volatile anaesthetic depth, all of which potentiate blockade.
4. Choose reversal: neostigmine for shallow non-depolarising block; sugammadex for aminosteroid moderate or deep block, urgent reversal, or when neostigmine is undesirable.
5. Confirm recovery: extubate only when TOF ratio is at least 0.9 and clinical criteria are satisfied.

Differential diagnosis of weakness after attempted reversal

Special situations

Cannot intubate cannot oxygenate rescue

Rocuronium 1.0 to 1.2 mg/kg provides intubating conditions comparable to suxamethonium but longer spontaneous recovery. Sugammadex 16 mg/kg can reverse profound rocuronium block rapidly, but it does not solve airway obstruction, laryngospasm, aspiration, failed ventilation or lack of oxygenation. In a true cannot intubate cannot oxygenate scenario, front-of-neck airway algorithms take priority. Sugammadex may be useful if oxygenation is maintained and return of spontaneous ventilation will improve safety, but it must not delay emergency oxygenation.

Renal failure

For cisatracurium or atracurium, organ-independent Hofmann degradation and ester hydrolysis may avoid reliance on renal excretion, but reversal with sugammadex is not available. For rocuronium in severe renal impairment, duration may be prolonged and sugammadex elimination is markedly reduced. If sugammadex is used because of clinical necessity, the patient should have quantitative monitoring and postoperative observation for recurrence.

Myasthenia gravis

Patients are highly sensitive to non-depolarising blockers and may already take anticholinesterases. Neostigmine reversal is unpredictable and may precipitate cholinergic effects. Rocuronium in very small titrated doses with sugammadex reversal is increasingly used, but postoperative respiratory failure may still occur due to disease, bulbar dysfunction or surgery. Quantitative monitoring and a planned postoperative respiratory strategy are essential.

Pregnancy and postpartum

Neostigmine with glycopyrronium has long obstetric experience. Sugammadex data in pregnancy are more limited, and its contraceptive interaction is relevant postpartum. In obstetric general anaesthesia, rapid safe reversal must be balanced against aspiration risk, airway oedema and urgency. Sugammadex may be valuable after rocuronium, but local policy and individual risk assessment matter.

Primary FRCA viva framing

A strong viva answer defines both drugs by mechanism, states dose ranges precisely, relates dose to depth of block, insists on quantitative monitoring, and recognises adverse effects. The key conceptual contrast is that neostigmine modifies the neurotransmitter environment at the synapse, whereas sugammadex removes the antagonist from the biophase by plasma binding. This explains almost every clinical difference between them.